C. Stach

4.6k total citations
45 papers, 2.2k citations indexed

About

C. Stach is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C. Stach has authored 45 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 22 papers in Immunology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C. Stach's work include Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (19 papers) and Systemic Lupus Erythematosus Research (14 papers). C. Stach is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (19 papers) and Systemic Lupus Erythematosus Research (14 papers). C. Stach collaborates with scholars based in Germany, United States and United Kingdom. C. Stach's co-authors include Georg Schett, Matthias Englbrecht, Bengt Hoepken, Atul Deodhar, Philip J. Mease, Désirée van der Heijde, Klaus Engelke, Reinhard Voll, Danuta Kielar and T. Arledge and has published in prestigious journals such as The Journal of Experimental Medicine, SHILAP Revista de lepidopterología and Cell Death and Differentiation.

In The Last Decade

C. Stach

40 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Stach Germany 19 1.5k 1.2k 448 280 222 45 2.2k
Serena Bugatti Italy 28 1.3k 0.8× 655 0.5× 301 0.7× 258 0.9× 349 1.6× 89 2.1k
Eva Dokoupilová Czechia 23 1.3k 0.8× 1.5k 1.2× 581 1.3× 130 0.5× 137 0.6× 54 2.1k
M. G. H. Van de Sande Netherlands 20 943 0.6× 540 0.4× 364 0.8× 150 0.5× 194 0.9× 55 1.3k
So‐Young Bang South Korea 24 846 0.6× 593 0.5× 128 0.3× 442 1.6× 174 0.8× 100 1.8k
G. Yanni United Kingdom 18 1.0k 0.7× 660 0.5× 232 0.5× 241 0.9× 219 1.0× 26 1.8k
Herbert Kellner Germany 17 762 0.5× 523 0.4× 307 0.7× 137 0.5× 123 0.6× 38 1.2k
Richard Newmark United States 13 1.1k 0.7× 873 0.7× 487 1.1× 793 2.8× 118 0.5× 16 2.4k
Valérie Devauchelle France 26 874 0.6× 876 0.7× 180 0.4× 280 1.0× 274 1.2× 57 2.2k
Stephen Kelly United Kingdom 18 800 0.5× 560 0.5× 229 0.5× 176 0.6× 151 0.7× 40 1.4k
Alessandra Nerviani United Kingdom 24 674 0.4× 925 0.7× 220 0.5× 495 1.8× 90 0.4× 49 1.8k

Countries citing papers authored by C. Stach

Since Specialization
Citations

This map shows the geographic impact of C. Stach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Stach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Stach more than expected).

Fields of papers citing papers by C. Stach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Stach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Stach. The network helps show where C. Stach may publish in the future.

Co-authorship network of co-authors of C. Stach

This figure shows the co-authorship network connecting the top 25 collaborators of C. Stach. A scholar is included among the top collaborators of C. Stach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Stach. C. Stach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Furie, Richard, Ian N Bruce, Thomas Dörner, et al.. (2021). Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Lara D. Veeken. 60(11). 5397–5407. 79 indexed citations
2.
Cleanthous, Sophie, Sabine Bongardt, Patrick Marquis, et al.. (2021). Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies. Rheumatology and Therapy. 8(3). 1287–1301. 9 indexed citations
3.
Stach, C., Victor S. Sloan, Thasia Woodworth, B. Kilgallen, & Daniel E. Furst. (2019). Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use. Drug Safety. 42(12). 1499–1506. 12 indexed citations
4.
5.
Maksymowych, Walter P., R. Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The Journal of Rheumatology. 41(7). 1496–1497. 3 indexed citations
6.
Rosenbaum, J. T., Martín Rudwaleit, Robert Landewé, et al.. (2014). Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.. Data Archiving and Networked Services (DANS). 66. 1 indexed citations
7.
Mease, Philip J., R. Fleischmann, J. Wollenhaupt, et al.. (2014). 210. Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure. Lara D. Veeken. 53(suppl_1). i137–i138. 14 indexed citations
8.
Mease, Philip, R Fleischmann, J. Wollenhaupt, et al.. (2013). EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. Lara D. Veeken. 52(10). 162–163. 4 indexed citations
9.
Wollenhaupt, J., D. Gladman, C. Stach, et al.. (2013). Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. The Journal of Rheumatology. 41(7). 1448–1449. 3 indexed citations
10.
11.
Mease, Philip J., Roy Fleischmann, Atul Deodhar, et al.. (2013). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the Rheumatic Diseases. 73(1). 48–55. 360 indexed citations
12.
Landewé, Robert, Martín Rudwaleit, Désirée van der Heijde, et al.. (2012). Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study. Data Archiving and Networked Services (DANS). 64(10). 10 indexed citations
13.
Finzel, Stephanie, et al.. (2011). 44 COMPARATIVE ANALYSIS OF BONE EROSIONS AND CYSTS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND EROSIVE HAND OSTEOARTHRITIS. Osteoarthritis and Cartilage. 19. S26–S26. 1 indexed citations
14.
Finzel, Stephanie, Sarah Ohrndorf, Matthias Englbrecht, et al.. (2011). A detailed comparative study of high‐resolution ultrasound and micro–computed tomography for detection of arthritic bone erosions. Arthritis & Rheumatism. 63(5). 1231–1236. 96 indexed citations
15.
Rech, Jürgen, S. Schmidt, Klaus Engelke, et al.. (2011). Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Annals of the Rheumatic Diseases. 70(9). 1587–1593. 106 indexed citations
16.
Fürnrohr, Barbara G., Sven Wach, Jennifer A. Kelly, et al.. (2010). Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 69(11). 1983–1989. 34 indexed citations
17.
Stach, C., Michael Bäuerle, Matthias Englbrecht, et al.. (2010). Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high‐resolution computed tomography. Arthritis & Rheumatism. 62(2). 330–339. 145 indexed citations
18.
Englbrecht, Matthias, et al.. (2010). A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Annals of the Rheumatic Diseases. 70(1). 122–127. 114 indexed citations
19.
Bondanza, Attilio, Valérie S. Zimmermann, Patrizia Rovere‐Querini, et al.. (2004). Inhibition of Phosphatidylserine Recognition Heightens the Immunogenicity of Irradiated Lymphoma Cells In Vivo. The Journal of Experimental Medicine. 200(9). 1157–1165. 143 indexed citations
20.
Stach, C., Javier Turnay, Reinhard Voll, et al.. (2000). Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death and Differentiation. 7(10). 911–915. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Serena Bugatti Breakdown of academic impact, for papers by Eva Dokoupilová Breakdown of academic impact, for papers by M. G. H. Van de Sande Breakdown of academic impact, for papers by So‐Young Bang Breakdown of academic impact, for papers by G. Yanni Breakdown of academic impact, for papers by Herbert Kellner Breakdown of academic impact, for papers by Richard Newmark Breakdown of academic impact, for papers by Valérie Devauchelle Breakdown of academic impact, for papers by Stephen Kelly Breakdown of academic impact, for papers by Alessandra Nerviani
Rankless by CCL
2026